MedTrace Logo

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT05008575 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-01-12

No results posted yet for this study

Summary

CAR technology has been used in T cell therapy and gets great success in treating hematological diseases. Following models of CAR T cells, CAR NK cell therapy has been one hot point. For myeloid malignancies, CD33 is widely expressed. Targeting CD33 surface antigens by CAR NK cells provides an off-the-shelf immune cell therapy.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

anti-CD33 CAR NK cells

6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion

DRUG

Fludarabine

recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

DRUG

Cytoxan

recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • xi zhang, MD/PhD · Department of Hematology, Xinqiao Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2022-12-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008575 on ClinicalTrials.gov